These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 33766049)

  • 1. Policy disparities in response to the first wave of COVID-19 between China and Germany.
    Zhang Y; Shi L; Chen H; Wang X; Sun G
    Int J Equity Health; 2021 Mar; 20(1):86. PubMed ID: 33766049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policy Disparities in Response to COVID-19 between China and South Korea.
    Chen H; Shi L; Zhang Y; Wang X; Sun G
    J Epidemiol Glob Health; 2021 Jun; 11(2):246-252. PubMed ID: 33876595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policy disparities in fighting COVID-19 among Japan, Italy, Singapore and China.
    Wang X; Shi L; Zhang Y; Chen H; Sun G
    Int J Equity Health; 2021 Jan; 20(1):33. PubMed ID: 33441144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hubei's Core Response Policies in the Early Stage of COVID-19.
    Zhang Y; Shi L; Chen H; Wang X; Sun G
    Biomed Res Int; 2021; 2021():6610045. PubMed ID: 34159196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy disparities in response to COVID-19 between Singapore and China.
    Wang X; Shi L; Zhang Y; Chen H; Sun G
    Int J Equity Health; 2021 Aug; 20(1):185. PubMed ID: 34404390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic Panel Data Modeling and Surveillance of COVID-19 in Metropolitan Areas in the United States: Longitudinal Trend Analysis.
    Oehmke TB; Post LA; Moss CB; Issa TZ; Boctor MJ; Welch SB; Oehmke JF
    J Med Internet Res; 2021 Feb; 23(2):e26081. PubMed ID: 33481757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. China's Public Health Policies in Response to COVID-19: From an "Authoritarian" Perspective.
    Gao J; Zhang P
    Front Public Health; 2021; 9():756677. PubMed ID: 34976920
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 in Germany and China: mitigation versus elimination strategy.
    Lu G; Razum O; Jahn A; Zhang Y; Sutton B; Sridhar D; Ariyoshi K; von Seidlein L; Müller O
    Glob Health Action; 2021 Jan; 14(1):1875601. PubMed ID: 33472568
    [No Abstract]   [Full Text] [Related]  

  • 9. Analyzing the effects of public interventions on reducing public gatherings in China during the COVID-19 epidemic via mobile terminals positioning data.
    Nie L; Guo X; Yi CQ; Wang RJ
    Math Biosci Eng; 2020 Jul; 17(5):4875-4890. PubMed ID: 33120532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Coronavirus Pandemic 1 Year On-What Went Wrong?
    Gostin LO
    JAMA; 2021 Mar; 325(12):1132-1133. PubMed ID: 33755061
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 Control: Can Germany Learn From China?
    Müller O; Lu G; Jahn A; Razum O
    Int J Health Policy Manag; 2020 Oct; 9(10):432-435. PubMed ID: 32610735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Countries of origin of imported COVID-19 cases into China and measures to prevent onward transmission.
    Zhang ZB; Li L; Qin PZ; Li K; Huang Y; Luo L; Ou CQ
    J Travel Med; 2020 Dec; 27(8):. PubMed ID: 32841347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of China's Hubei control strategy for COVID-19 epidemic: an observational study.
    Liu Y; Zheng F; Du Z; Li J; Gu J; Jiang M; Yoneoka D; Gilmour S; Hao Y
    BMC Infect Dis; 2021 Aug; 21(1):820. PubMed ID: 34399697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Surveillance in the Middle East and North Africa: Longitudinal Trend Analysis.
    Post L; Marogi E; Moss CB; Murphy RL; Ison MG; Achenbach CJ; Resnick D; Singh L; White J; Boctor MJ; Welch SB; Oehmke JF
    J Med Internet Res; 2021 Jan; 23(1):e25830. PubMed ID: 33302252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of China's Lockdown Policy on the Incidence of COVID-19: An Interrupted Time Series Analysis.
    Molefi M; Tlhakanelo JT; Phologolo T; Hamda SG; Masupe T; Tsima B; Setlhare V; Mashalla Y; Wiebe DJ
    Biomed Res Int; 2021; 2021():9498029. PubMed ID: 34722775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of China's Prevention and Control Strategy for the COVID-19 Epidemic.
    Wang J; Wang Z
    Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32225019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of household quarantine on SARS-Cov-2 infection in mainland China: A mean-field modelling approach.
    Yang JY; Wang GQ; Zhang S
    Math Biosci Eng; 2020 Jun; 17(5):4500-4512. PubMed ID: 33120515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic lockdown, healthcare policies and human rights: integrating opposed views on COVID-19 public health mitigation measures.
    Burlacu A; Crisan-Dabija R; Covic A; Raiu C; Mavrichi I; Popa IV; Lillo-Crespo M
    Rev Cardiovasc Med; 2020 Dec; 21(4):509-516. PubMed ID: 33387996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. China's model to combat the COVID-19 epidemic: a public health emergency governance approach.
    Ning Y; Ren R; Nkengurutse G
    Glob Health Res Policy; 2020; 5():34. PubMed ID: 32685691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Legal Response to COVID-19: Legal Pathways to a More Effective and Equitable Response.
    Burris S; de Guia S; Gable L; Levin D; Parmet WE; Terry NP
    J Public Health Manag Pract; 2021; 27 Suppl 1, COVID-19 and Public Health: Looking Back, Moving Forward():S72-S79. PubMed ID: 33239567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.